Sacubitril/Allisartan Isoproxil/Amlodipine Besylate

沙库巴曲/阿利沙坦酯/苯磺酸氨氯地平

Report date: 2026/04/08 15:41:48

Base Information

Drug NameSacubitril/Allisartan Isoproxil/Amlodipine Besylate
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionNeprilysin inhibitorsAngiotensin II Receptor Type 1 antagonistsVoltage-gated calcium channel blockers
TargetsNeprilysinAngiotensin II Receptor Type 1Voltage-gated calcium channel
Therapy Area/IndicationsEssential Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes SacubitrilAllisartan IsoproxilAmlodipine Besylate
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Salubris Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Salubris Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsEssential Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A